We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Inspection of Impax’s Taiwan Facility Reveals Manufacturing Issues
FDA Inspection of Impax’s Taiwan Facility Reveals Manufacturing Issues
An FDA inspection of Impax Laboratories’ Taiwan plant has uncovered apparent manufacturing violations, raising new questions about the company’s plans to launch its proposed Parkinson’s disease drug Rytary.